No Data
Adidas Bio-B (02197) SCB-1019: Potentially the best in its class, reshaping the global RSV market landscape.
With its unique Trimer-Tag technology platform, Clover Biopharmaceuticals' RSV candidate vaccine SCB-1019 is expected to become a potential best-in-class, reshaping the market landscape of RSV vaccines~
Hong Kong healthcare stocks receive attention from investors again, with Trifolium Biotech surging nearly 15%.
1. What is the impact of medical insurance negotiations on pharmaceutical stocks? 2. What are the reasons for the rise of Clover Biopharmaceuticals and Imin Ankang?
HK Stock Market Update | TriClover Bio-B (02197) surged over 14% Positive Phase I research results for Bivalent RSV Vaccine.
Adidas AG-B (02197) rose more than 14%, as of the time of writing, it increased by 14.75%, reaching 0.35 Hong Kong dollars, with a turnover of 0.8356 million Hong Kong dollars.
Adidas Biologics-B (02197.HK) announced positive clinical data from the head-to-head comparison of its bivalent RSV candidate vaccine SCB-1019 with the GSK RSV vaccine AREXVY.
Grain News October 29th | Trifolium Biotech-B (02197.HK) announced that in Phase I clinical trials, the unadjuvanted bivalent RSV PreF trimer subunit candidate vaccine SCB-1019 (developed based on Trifolium Biotech's unique Trimer-Tag protein trimerization vaccine technology platform) was compared head-to-head with GSK's RSV vaccine AREXVY using AS01E adjuvant, obtaining more positive immunogenicity and safety data in elderly subjects.
Express News | National Medical Products Administration: Deploys pilot work on segmented production reform of biological products.
Express News | Hong Kong healthcare stocks are strong, with Lai Kaimedicine rising nearly 14%.
No Data
No Data